Radiomic Analysis in Contrast-Enhanced Spectral Mammography for Predicting Breast Cancer Histological Outcome.
Her2 positive
breast cancer
correlation
histological outcome
prediction
radiomic analysis
triple negative
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
17 Sep 2020
17 Sep 2020
Historique:
received:
26
08
2020
revised:
07
09
2020
accepted:
16
09
2020
entrez:
22
9
2020
pubmed:
23
9
2020
medline:
23
9
2020
Statut:
epublish
Résumé
Contrast-Enhanced Spectral Mammography (CESM) is a recently introduced mammographic method with characteristics particularly suitable for breast cancer radiomic analysis. This work aims to evaluate radiomic features for predicting histological outcome and two cancer molecular subtypes, namely Human Epidermal growth factor Receptor 2 (HER2)-positive and triple-negative. From 52 patients, 68 lesions were identified and confirmed on histological examination. Radiomic analysis was performed on regions of interest (ROIs) selected from both low-energy (LE) and ReCombined (RC) CESM images. Fourteen statistical features were extracted from each ROI. Expression of estrogen receptor (ER) was significantly correlated with variation coefficient and variation range calculated on both LE and RC images; progesterone receptor (PR) with skewness index calculated on LE images; and Ki67 with variation coefficient, variation range, entropy and relative smoothness indices calculated on RC images. HER2 was significantly associated with relative smoothness calculated on LE images, and grading tumor with variation coefficient, entropy and relative smoothness calculated on RC images. Encouraging results for differentiation between ER+/ER-, PR+/PR-, HER2+/HER2-, Ki67+/Ki67-, High-Grade/Low-Grade and TN/NTN were obtained. Specifically, the highest performances were obtained for discriminating HER2+/HER2- (90.87%), ER+/ER- (83.79%) and Ki67+/Ki67- (84.80%). Our results suggest an interesting role for radiomics in CESM to predict histological outcomes and particular tumors' molecular subtype.
Identifiants
pubmed: 32957690
pii: diagnostics10090708
doi: 10.3390/diagnostics10090708
pmc: PMC7555402
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Radiol. 2019 Aug;29(8):4456-4467
pubmed: 30617495
J Magn Reson Imaging. 2012 Jul;36(1):145-51
pubmed: 22392859
J Magn Reson Imaging. 2015 Oct;42(4):902-7
pubmed: 25777181
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Mol Imaging Biol. 2020 Jun;22(3):780-787
pubmed: 31463822
Korean J Radiol. 2020 Jul;21(7):779-792
pubmed: 32524780
PLoS One. 2017 Feb 6;12(2):e0171683
pubmed: 28166261
Radiology. 2019 Apr;291(1):15-20
pubmed: 30747591
Breast Cancer. 2015 Sep;22(5):496-502
pubmed: 24402638
Insights Imaging. 2017 Feb;8(1):11-18
pubmed: 27854006
J Magn Reson Imaging. 2015 Oct;42(4):920-4
pubmed: 25758675
Bioinformatics. 2005 Aug 1;21(15):3301-7
pubmed: 15905277
Eur Radiol. 2019 Apr;29(4):1799-1808
pubmed: 30324386
Radiology. 2014 Nov;273(2):365-72
pubmed: 25028781
BMC Bioinformatics. 2020 Mar 11;21(Suppl 2):91
pubmed: 32164532
Eur Radiol Exp. 2019 Aug 14;3(1):36
pubmed: 31414273
Breast Cancer Res. 2019 Sep 12;21(1):106
pubmed: 31514736
Phys Med Biol. 2019 Oct 23;64(21):215001
pubmed: 31470420
Ecancermedicalscience. 2015 Aug 06;9:562
pubmed: 26316883
Eur Radiol. 2015 Oct;25(10):2813-20
pubmed: 25813015
Biomed Res Int. 2018 May 16;2018:9032408
pubmed: 30140703
J Clin Med. 2019 Jun 21;8(6):
pubmed: 31234363
NPJ Breast Cancer. 2016;2:
pubmed: 27853751
Biomed Res Int. 2018 Oct 8;2018:6120703
pubmed: 30402486
Clin Transl Oncol. 2020 Jan;22(1):50-59
pubmed: 30977048
Clin Radiol. 2018 Aug;73(8):715-723
pubmed: 29937340
Mol Imaging Biol. 2020 Apr;22(2):453-461
pubmed: 31209778
Breast. 2018 Aug;40:92-96
pubmed: 29723697
Phys Med. 2019 Aug;64:1-9
pubmed: 31515007
Sci Rep. 2020 Jun 17;10(1):9807
pubmed: 32555338
AJR Am J Roentgenol. 2012 Sep;199(3):654-63
pubmed: 22915408
Breast Cancer Res Treat. 2014 Jul;146(2):371-81
pubmed: 24986697
Eur J Radiol. 2019 Apr;113:148-152
pubmed: 30927939
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Diagnostics (Basel). 2020 Jul 18;10(7):
pubmed: 32708512
PLoS One. 2015 Nov 24;10(11):e0143308
pubmed: 26600392
Contrast Media Mol Imaging. 2018 Jan 17;2018:5076269
pubmed: 29581709
Radiology. 2013 Oct;269(1):8-15
pubmed: 24062559
PLoS One. 2020 Jun 26;15(6):e0234871
pubmed: 32589681
Breast Cancer Res Treat. 2018 Jun;169(2):217-229
pubmed: 29396665